Seikagaku Corporation, though small in size, has many strengths and unique profile.
Seikagaku began focusing on glycoscience more than a half century ago, when the importance of glycoconjugates had not yet been recognized, and has been working on applied research for drug development ever since. During this time, we have worked to support related academic societies and symposia, and have created a worldwide network of researchers. These efforts led us to successfully develop joint function improving agent ARTZ, which is currently our main product.
The field of glycoscience is a niche field that remains hard for the major pharmaceutical companies to penetrate. Seikagaku, though small, is proud to be an internationally competitive pharmaceutical company that specializes in this special field.
Our unique extraction and purification technologies were the key to our success in producing the world's first chondroitin sulfate. These technologies allowed us to successfully extract and highly purify hyaluronic acid, an achievement that had not previously been accomplished. Seikagaku will continue to use its own technologies and know-how to develop and manufacture innovative drugs, and to supply high quality products to the market.
Seikagaku does not have its own sales force. Instead, we offer our products through sales partners that have strengths in their respective product fields. By maintaining a slim organizational structure, we are able to focus our management resources on R&D and production. This is evidenced by the facts that our R&D expenditures account for about 20% of net sales, and about one-third of our employees are involved in R&D. We intend to retain this business model, keeping our focus on R&D.